CAS: 1819363-80-8; (E)-1-(2-Hydroxyphenyl)-3-((1R,4R)-5-(Pyridin-2-yl)-2,5-Diazabicyclo[2.2.1]Heptan-2-yl)Prop-2-En-1-One
- 英文名称(E)-1-(2-Hydroxyphenyl)-3-((1R,4R)-5-(Pyridin-2-yl)-2,5-Diazabicyclo[2.2.1]Heptan-2-yl)Prop-2-En-1-One
- 中文名称(2E)-1-(2-羟基苯基)-3-[(1R,4R)-5-(2-吡啶基)-2,5-二氮杂双环[2.2.1]庚烷-2-基]-2-丙烯-1-酮
- IUPAC名称(E)-1-(2-hydroxyphenyl)-3-((1R,4R)-5-(pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)prop-2-en-1-one
- 其它别名(E)-1-(2-Hydroxyphenyl)-3-((1R,4R)-5-(Pyridin-2-yl)-2,5-Diazabicyclo[2.2.1]Heptan-2-yl)Prop-2-En-1-One; Pfi 3
- CAS编号1819363-80-8
- MFCD编号:MFCD28100807
- 分子式:C19H19N3O2分子量:321.38
- 产品CID: 936310
- 产品分类Chemistry → Heterocyclic Building Blocks → Aromatic Heterocycles | Inhibitors/Agonists → Epigenetics → Epigenetic Reader Domain | Piperazines
物理性质
- 密度1.347±0.06 g/cm3 (20 ºC 760 Torr),
- PSA:56.67
- LogP:2.4496
- 溶解性Soluble In DMSO (>25 mg/mL)
- 外观形态黄色至橙色粉末
- 储存条件2-8°C
- 产品应用该化合物是针对SMARCA溴域的选择性化学探测器,包括SMACA2,SMALCA4,和PB1(5)溴域素;它是蛋白质-蛋白相互作用的强大和细胞活性抑制剂,有选择地与核心BAF溴域网捆绑;它显示了对36个其他测试过的电动酶的高度选择性,并显示在屏幕上对102个细胞表面受体和30个酶的离目标效果最小,只有4个气相化学反应器的微摩粒亲近性,与非BRD家庭蛋白没有相互作用;PFFI3调制基因表达方案对干细胞分辨至关重要,并且通过在转录起始点增加压性H3K27MM3标记和STAT3约束性,从而对BRG1损失的影响.
上下游产品
tert-butyl (1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 2-bromo-pyridine chromone-3-carboxylic acid合成工艺路线路线简述
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2902600000-乙苯
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Fedorov O, Castex J, Tallant C, Owen DR, Martin S, Aldeghi M, Monteiro O, Filippakopoulos P, Picaud S, Trzupek JD, Gerstenberger BS, Bountra C, Willmann D, Wells C, Philpott M, Rogers C, Biggin PC, Brennan PE, Bunnage ME, Schüle R, Günther T, Knapp S, Müller S. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Sci Adv. 2015 Nov 13;1(10):e1500723. doi: 10.1126/sciadv.1500723. eCollection 2015 Nov.
2: Vangamudi B, Paul TA, Shah PK, Kost-Alimova M, Nottebaum L, Shi X, Zhan Y, Leo E, Mahadeshwar HS, Protopopov A, Futreal A, Tieu TN, Peoples M, Heffernan TP, Marszalek JR, Toniatti C, Petrocchi A, Verhelle D, Owen DR, Draetta G, Jones P, Palmer WS, Sharma S, Andersen JN. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. Cancer Res. 2015 Sep 15;75(18):3865-78. doi: 10.1158/0008-5472.CAN-14-3798. Epub 2015 Jul 2.
📝 需求与反馈
尽可能描述清楚需求与问题信息
